Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome. — CFSMEATLAS
Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome.
Apostolou, Eirini, Rizwan, Muhammad, Moustardas, Petros et al. · Frontiers in immunology · 2022 · DOI
Quick Summary
This study found that people with ME/CFS have a different immune response to COVID-19 compared to healthy people, even when the COVID infection is mild. Specifically, the researchers discovered that after COVID-19, dormant viruses (like EBV and others) reactivate more strongly in people with ME/CFS, as shown by antibody patterns in saliva. This suggests that COVID-19 may trigger hidden virus reactivation that could contribute to fatigue symptoms in ME/CFS patients.
Why It Matters
This research provides evidence that ME/CFS patients may have a fundamentally different way of responding to viral infections, particularly COVID-19, which could explain why some people develop post-viral fatigue syndromes. Understanding that latent virus reactivation occurs in saliva (local immunity) rather than just in the blood may help explain why standard blood tests sometimes miss these abnormalities, and opens new avenues for diagnosis and treatment research.
Observed Findings
ME/CFS patients showed significantly stronger salivary antibody responses to latent viruses 3-6 months after mild/asymptomatic COVID-19 compared to healthy controls.
EBV-encoded nuclear antigen-1 (EBNA-1) IgG was elevated in saliva of ME/CFS patients post-infection but not in healthy donors.
EBV-VCA IgG was elevated at baseline in ME/CFS patients even before SARS-CoV-2 infection, suggesting chronic activation of this virus.
Latent virus reactivation (EBV, HHV-6, HERV-K) was detectable in saliva but not consistently in plasma, indicating local mucosal immunity findings.
Inferred Conclusions
ME/CFS patients have a chronically altered anti-viral immune profile characterized by sustained activation against latent herpesviruses.
Even mild or asymptomatic SARS-CoV-2 infection is a potent trigger for reactivation of latent herpesviruses and endogenous retroviruses, particularly in ME/CFS patients.
Salivary antibody fingerprints may be more sensitive than plasma antibodies for detecting latent virus reactivation in post-viral syndromes.
The heightened immune response to latent viruses in ME/CFS patients may contribute to ongoing fatigue and post-viral symptoms.
Remaining Questions
Does latent virus reactivation directly cause or perpetuate ME/CFS symptoms, or is it merely an epiphenomenon of altered immunity?
What This Study Does Not Prove
This study does not prove that latent virus reactivation causes ME/CFS symptoms or functional decline—it only shows that the antibody pattern differs between groups. The cross-sectional design cannot establish causation or temporal relationships between reactivation and symptom onset. The findings also cannot be generalized to vaccinated individuals, as the study enrolled only non-vaccinated participants.
Can this salivary antibody pattern be used as a diagnostic biomarker for ME/CFS, and does it correlate with symptom severity or post-exertional malaise?
What mechanisms drive the differential immune response in ME/CFS patients, and are there genetic or immunological factors that predispose certain individuals to this pattern?
Do antiviral treatments or immune modulation strategies that target latent virus reactivation improve outcomes in ME/CFS or long-COVID patients?